In a blog post, FDA Commissioner Scott Gottlieb discusses the new Biotech Working Group formed in early May. The working group is comprised of representatives from multiple FDA centers and offices. In the coming months, FDA will release an action plan that ensures a “flexible regulatory framework for evaluating the safety of products that also supports plant and animal bio- technology innovation.”
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
